AT&T Inc. vs Zimmer Biomet Holdings Inc — how do they compare? AT&T Inc. trades at $24.42 (market cap $167.88B), while Zimmer Biomet Holdings Inc trades at $97.27 (market cap $18.55B). The key difference: AT&T Inc. is far larger — about 9.1× Zimmer Biomet Holdings Inc's market cap, and AT&T Inc. pays the higher dividend (4.53%). Which is the better fit depends on your goals.
| T | ZBH | |
|---|---|---|
Market Cap | $167.88B | $18.55B |
Sector | Media | Health |
52-Week High | $29.62 | $107.71 |
52-Week Low | $20.49 | $79.58 |
Enterprise Value | $313.20B | $25.61B |
Dividend Yield | 4.53% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $24.08, up 1.18% with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.65 exceeding expectations. Valuation remains attractive with a P/E of 8.1 and dividend yield of 4.7%. Recent developments include fiber expansion and AI initiatives, while cash flow improved to $15.1B in 2025. Technical indicators show bullish moving averages with resistance near $24-25.
Outlook remains positive with 15% upside to consensus price target of $27.69. Investment appeal includes strong cash flow generation, dividend sustainability, and ongoing network investments. Key risks include competitive pressure from SpaceX's wireless ambitions and execution challenges in fiber deployment. Analyst consensus leans bullish with 41% buy ratings versus 10% sell recommendations.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →